Janssen Pharms Drug Patent Portfolio
Janssen Pharms owns 22 orange book drugs protected by 122 US patents with Razadyne Er having the least patent protection, holding only 1 patent. And Risperdal Consta with maximum patent protection, holding 24 patents. Given below is the list of Janssen Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11666697 | Methods for ensuring resuspension of paliperidone palmitate formulations | 24 Nov, 2041 | Active |
| US11304951 | Dosing regimens associated with extended release paliperidone injectable formulations | 07 May, 2041 | Active |
| US11324751 | Dosing regimens associated with extended release paliperidone injectable formulations | 07 May, 2041 | Active |
| US12208100 | Dosing regimens associated with extended release paliperidone injectable formulations | 07 May, 2041 | Active |
| US11883526 | Esketamine for the treatment of depression | 18 Feb, 2040 | Active |
| US10828310 | Reducing the risk of cardiovascular events | 31 Jul, 2039 | Active |
| US10828310 | Reducing the risk of cardiovascular events | 31 Jan, 2039 | Active |
| US10143693 | Dosing regimen for missed doses for long-acting injectable paliperidone esters | 05 Apr, 2036 | Active |
| US10869844 | Methods for the treatment of depression | 10 Sep, 2035 | Active |
| US11173134 | Methods for the treatment of depression | 10 Sep, 2035 | Active |
| US11311500 | Methods for the treatment of depression | 10 Sep, 2035 | Active |
| US9539218 | Prevention and treatment of thromboembolic disorders | 17 Aug, 2034 | Active |
| US11446260 | Pharmaceutical composition of S-ketamine hydrochloride | 14 Mar, 2034 | Active |
| US9539218 | Prevention and treatment of thromboembolic disorders | 17 Feb, 2034 | Active |
| US8785500 | Intranasal administration of ketamine to treat depression | 05 Mar, 2033 | Active |
| US10617668 | Pharmaceutical formulations | 11 Nov, 2031 | Active |
| US10617668 | Pharmaceutical formulations | 11 May, 2031 | Active |
| US9439906 | Dosing regimen associated with long acting injectable paliperidone esters | 26 Jan, 2031 | Active |
| US11576894 | Combination therapy for the treatment of diabetes | 06 Jul, 2030 | Active |
| US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | 26 Aug, 2029 | Active |
| US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | 26 Feb, 2029 | Active |
| US8513202 | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | 03 Jun, 2028 | Active |
| US7943788 | Glucopyranoside compound | 14 Jan, 2028 | Active |
| US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | 03 Dec, 2027 | Active |
| US7943788 | Glucopyranoside compound | 14 Jul, 2027 | Active |
| US9592207 | Intranasal administration of ketamine to treat depression | 20 Mar, 2027 | Active |
| US8222219 | Glucopyranoside compound | 11 Oct, 2025 | Active |
| US9415053 | Solid, orally administrable pharmaceutical composition | 13 May, 2025 | Expired |
| US8222219 | Glucopyranoside compound | 11 Apr, 2025 | Expired |
| US7157456 | Substituted oxazolidinones and their use in the field of blood coagulation | 28 Feb, 2025 | Expired |
| US9415053 | Solid, orally administrable pharmaceutical composition | 13 Nov, 2024 | Expired |
| US7157456 | Substituted oxazolidinones and their use in the field of blood coagulation | 28 Aug, 2024 | Expired |
| US8785403 | Glucopyranoside compound | 30 Jul, 2024 | Expired |
| US6806256 | Taste masked liquid pharmaceutical compositions | 26 Aug, 2022 | Expired |
| US6806256 | Taste masked liquid pharmaceutical compositions | 26 Feb, 2022 | Expired |
| US6723340 | Optimal polymer mixtures for gastric retentive tablets | 25 Oct, 2021 | Expired |
| US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation | 11 Dec, 2020 | Expired |
| US7592339 | Substituted oxazolidinones and their use in the field of blood coagulation | 11 Dec, 2020 | Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability | 25 Nov, 2020 | Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US6339105 | Analgesic regimen | 12 Apr, 2020 | Expired |
| US7160559 | Controlled release galantamine composition | 20 Dec, 2019 | Expired |
| US6214815 | Triphasic oral contraceptive | 09 Dec, 2019 | Expired |
| US6339105 | Analgesic regimen | 12 Oct, 2019 | Expired |
| US7125560 | Pharmaceutical composition of topiramate | 01 Sep, 2019 | Expired |
| US6194006 | Preparation of microparticles having a selected release profile | 30 Jun, 2019 | Expired |
| US6379703 | Preparation of microparticles having a selected release profile | 30 Jun, 2019 | Expired |
| US6596316 | Preparation of microparticles having a selected release profile | 30 Jun, 2019 | Expired |
| US6407079 | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | 18 Jun, 2019 | Expired |
| US6214815 | Triphasic oral contraceptive | 09 Jun, 2019 | Expired |
| US6555544 | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters | 10 May, 2019 | Expired |
| US7125560 | Pharmaceutical composition of topiramate | 01 Mar, 2019 | Expired |
| US6194006 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US6379703 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US6596316 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US6555544 | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters | 10 Nov, 2018 | Expired |
| US6919373 | Methods and devices for providing prolonged drug therapy | 31 Jan, 2018 | Expired |
| US6930129 | Methods and devices for providing prolonged drug therapy | 31 Jan, 2018 | Expired |
| US8163798 | Methods and devices for providing prolonged drug therapy | 31 Jan, 2018 | Expired |
| US8629179 | Methods and devices for providing prolonged drug therapy | 31 Jan, 2018 | Expired |
| US9000038 | Methods and devices for providing prolonged drug therapy | 31 Jan, 2018 | Expired |
| US6224905 | Biconvex rapidly disintegrating dosage forms | 10 Dec, 2017 | Expired |
| US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters | 12 Nov, 2017 | Expired |
| US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent | 02 Nov, 2017 | Expired |
| US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 Nov, 2017 | Expired |
| US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 Nov, 2017 | Expired |
| US6919373 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US6930129 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US8163798 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US8629179 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US9000038 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US9029416 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US9144549 | Methods and devices for providing prolonged drug therapy | 31 Jul, 2017 | Expired |
| US6224905 | Biconvex rapidly disintegrating dosage forms | 10 Jun, 2017 | Expired |
| US6099863 | Fast-dissolving galanthamine hydrobromide tablet | 06 Jun, 2017 | Expired |
| US6358527 | Fast-dissolving galanthamine hydrobromide tablet | 06 Jun, 2017 | Expired |
| US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters | 12 May, 2017 | Expired |
| US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
| US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
| US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
| US5998380 | Treatment of migraine | 13 Apr, 2016 | Expired |
| US6503884 | Migraine treatment method using topiramate and related compounds | 13 Apr, 2016 | Expired |
| US7018983 | Treatment of migraine | 13 Apr, 2016 | Expired |
| US7498311 | Treatment of migraine | 13 Apr, 2016 | Expired |
| US5674895 | Dosage form comprising oxybutynin | 22 Nov, 2015 | Expired |
| US5840754 | Dosage form comprising oxybutynin | 22 Nov, 2015 | Expired |
| US5912268 | Dosage form and method for treating incontinence | 22 Nov, 2015 | Expired |
| US6262115 | Method for the management of incontinence | 22 Nov, 2015 | Expired |
| US5876746 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen | 20 Nov, 2015 | Expired |
| US5565447 | Indole derivatives | 07 Nov, 2015 | Expired |
| US5998380 | Treatment of migraine | 13 Oct, 2015 | Expired |
| US6503884 | Migraine treatment method using topiramate and related compounds | 13 Oct, 2015 | Expired |
| US7018983 | Treatment of migraine | 13 Oct, 2015 | Expired |
| US7498311 | Treatment of migraine | 13 Oct, 2015 | Expired |
| US5972377 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen | 07 Jun, 2015 | Expired |
| US5674895 | Dosage form comprising oxybutynin | 22 May, 2015 | Expired |
| US5840754 | Dosage form comprising oxybutynin | 22 May, 2015 | Expired |
| US5912268 | Dosage form and method for treating incontinence | 22 May, 2015 | Expired |
| US6262115 | Method for the management of incontinence | 22 May, 2015 | Expired |
| US5688801 | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 18 May, 2015 | Expired |
| US5565447 | Indole derivatives | 07 May, 2015 | Expired |
| US5648093 | Pharmaceutical and other dosage forms | 15 Jan, 2015 | Expired |
| US5707975 | Oral formulations on an antifungal | 13 Jan, 2015 | Expired |
| US5453425 | Risperidone oral formulation | 11 Jan, 2015 | Expired |
| USRE39181 | Aqueous risperidone formulations | 11 Jan, 2015 | Expired |
| US5688801 | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 18 Nov, 2014 | Expired |
| US5648093 | Pharmaceutical and other dosage forms | 15 Jul, 2014 | Expired |
| US5453425 | Risperidone oral formulation | 11 Jul, 2014 | Expired |
| USRE39181 | Aqueous risperidone formulations | 11 Jul, 2014 | Expired |
| US5633015 | Beads having a core coated with an antifungal and a polymer | 27 May, 2014 | Expired |
| US5965168 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 May, 2014 | Expired |
| US6110921 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 May, 2014 | Expired |
| US6368632 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 May, 2014 | Expired |
| US7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 May, 2014 | Expired |
| US5254556 | 3-piperidinyl-1,2-benzisoxazoles | 15 Apr, 2014 | Expired |
| US5965168 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 Nov, 2013 | Expired |
| US6110921 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 Nov, 2013 | Expired |
| US6368632 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 Nov, 2013 | Expired |
| US7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | 19 Nov, 2013 | Expired |
| US5254556 | 3-piperidinyl-1,2-benzisoxazoles | 15 Oct, 2013 | Expired |
| US5352459 | Use of purified surface modifiers to prevent particle aggregation during sterilization | 16 Jun, 2013 | Expired |
| US5352459 | Use of purified surface modifiers to prevent particle aggregation during sterilization | 16 Dec, 2012 | Expired |
Latest Legal Activities on Janssen Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Janssen Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jun, 2024 | US9539218 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2024 | US10869844 |
|
Expire Patent
Critical
| 27 May, 2024 | US8163798 |
|
Expire Patent
Critical
| 20 May, 2024 | US10617668 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828310 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9439906 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2024 | US9415053 |
|
Recordation of Patent Grant Mailed
Critical
| 30 Jan, 2024 | US11883526 |
|
Email Notification
Critical
| 30 Jan, 2024 | US11883526 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 30 Jan, 2024 | US11883526 |
| Mail Patent eGrant Notification | 30 Jan, 2024 | US11883526 |
| Recordation of Patent eGrant | 30 Jan, 2024 | US11883526 |
| Patent eGrant Notification | 30 Jan, 2024 | US11883526 |
|
Email Notification
Critical
| 11 Jan, 2024 | US11883526 |
|
Issue Notification Mailed
Critical
| 10 Jan, 2024 | US11883526 |
Janssen Pharms's Drug Patent Litigations
Janssen Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2000, against patent number US6407079. The petitioner , challenged the validity of this patent, with PITHA V. MULLER as the respondent. Click below to track the latest information on how companies are challenging Janssen Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10828310 | February, 2022 |
Final Written Decision - Appealed
(28 Jul, 2023)
| Bayer Pharma AG et al. | Mylan Pharmaceuticals Inc. et al. |
| US10828310 | September, 2022 |
Final Written Decision
(28 Jul, 2023)
| Bayer Pharma AG et al. | InvaGen Pharmaceuticals, Inc. et al. |
| US10828310 | September, 2022 |
Final Written Decision
(28 Jul, 2023)
| Bayer Pharma AG et al. | Teva Pharmaceuticals USA, Inc |
| US9439906 | February, 2020 |
Terminated-Denied
(16 Sep, 2020)
| Janssen Pharmaceutica NV | Mylan Laboratories Ltd. |
| US9539218 | May, 2018 |
Terminated-Denied
(03 Dec, 2018)
| Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc. |
| US6667061 | May, 2016 |
FWD Entered
(28 Nov, 2017)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
| US7157456 | October, 2016 |
Terminated
(29 Mar, 2017)
| Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc et al. |
| US7585860 | October, 2016 |
Terminated
(29 Mar, 2017)
| Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US7592339 | October, 2016 |
Terminated
(29 Mar, 2017)
| Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US6667061 | May, 2016 |
Terminated-Denied
(30 Nov, 2016)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
| US9539218 | January, 2014 |
Decision
(01 Jun, 2016)
| Frank Misselwitz et al | |
| US6723340 | April, 2014 |
Final Written Decision
(16 Sep, 2015)
| DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6723340 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6407079 | October, 2000 |
Decision
(05 Oct, 2000)
| PITHA V. MULLER | |
Janssen Pharms Drug Patents' Oppositions Filed in EPO
Janssen Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 12, 2008, by Ratiopharm Gmbh. This opposition was filed on patent number EP04797879A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP08863534A | Dec, 2021 | EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Zentiva k.s. | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Hoffmann Eitle SLU | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Farmaprojects S.A.U. | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Gill Jennings & Every LLP | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Laboratorios Lesvi, S.L. | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Tolmar International Limited | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Sun Pharmaceutical Industries Europe B.V. | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | BIOGARAN | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Hoffmann Eitle | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | EVER Valinject GmbH | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Abbott Products Operations AG | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Maiwald Patent- und Rechtsanwaltsgesellschaft mbH | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Instone, Terry/Appleyard Lees IP LLP/Read, Howard | Granted and Under Opposition |
| EP08863534A | Dec, 2021 | Advanz Pharma Services (UK) Ltd. | Granted and Under Opposition |
| EP06706291A | Apr, 2021 | Krka, d.d., Novo mesto | Opposition rejected |
| EP08863534A | Mar, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP06706291A | Mar, 2021 | Zentiva Group, a.s. | Opposition rejected |
| EP16777058A | Jan, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | Hexal AG | Granted and Under Opposition |
| EP16777058A | Jan, 2021 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP16777058A | Dec, 2020 | Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP | Granted and Under Opposition |
| EP10735109A | Jan, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10735109A | Jan, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP14194507A | Jun, 2018 | Galenicum Health S.L. | Patent maintained as amended |
| EP14194507A | Jun, 2018 | Generics (UK) Ltd | Patent maintained as amended |
| EP11721616A | Apr, 2017 | LEK Pharmaceuticals d.d. | Revoked |
| EP06706291A | Jan, 2016 | ABG Patentes, S.L. | Opposition rejected |
| EP06706291A | Jan, 2016 | Galenicum Health S.L. | Opposition rejected |
| EP06706291A | Jan, 2016 | Hexal AG | Opposition rejected |
| EP06706291A | Jan, 2016 | Kraus & Weisert Patentanwälte PartGmbB | Opposition rejected |
| EP06706291A | Jan, 2016 | Stolmár, Matthias | Opposition rejected |
| EP06706291A | Jan, 2016 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Opposition rejected |
| EP06706291A | Jan, 2016 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Opposition rejected |
| EP06706291A | Jan, 2016 | Teva Pharmaceutical Industries Ltd. | Opposition rejected |
| EP06706291A | Jan, 2016 | Generics [UK] Limited (trading as Mylan) | Opposition rejected |
| EP06706291A | Jan, 2016 | STADA Arzneimittel AG | Opposition rejected |
| EP06706291A | Jan, 2016 | Wittkopp, Alexander | Opposition rejected |
| EP06706291A | Jan, 2016 | Actavis Group PTC ehf | Opposition rejected |
| EP06706291A | Jul, 2015 | Breuer, Markus | Opposition rejected |
| EP07850306A | Nov, 2014 | Galenicum Health S.L. | Patent maintained as amended |
| EP04771314A | Oct, 2013 | Galenicum Health S.L. | Patent maintained as amended |
| EP2006000431W | Jan, 2012 | Spanolux N.V.- DIV. Balterio | Opposition rejected |
| EP04797879A | Nov, 2008 | Ratiopharm GmbH | Patent maintained as amended |
Janssen Pharms's Family Patents
Janssen Pharms Drug List
Given below is the complete list of Janssen Pharms's drugs and the patents protecting them.
1. Axert
Axert is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5565447
(Pediatric)
| Indole derivatives |
07 Nov, 2015
(9 years ago)
| Expired |
| US5565447 | Indole derivatives |
07 May, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axert's drug page
2. Concerta
Concerta is protected by 12 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6919373
(Pediatric)
| Methods and devices for providing prolonged drug therapy |
31 Jan, 2018
(7 years ago)
| Expired |
| US6930129
(Pediatric)
| Methods and devices for providing prolonged drug therapy |
31 Jan, 2018
(7 years ago)
| Expired |
| US8163798
(Pediatric)
| Methods and devices for providing prolonged drug therapy |
31 Jan, 2018
(7 years ago)
| Expired |
| US8629179
(Pediatric)
| Methods and devices for providing prolonged drug therapy |
31 Jan, 2018
(7 years ago)
| Expired |
| US9000038
(Pediatric)
| Methods and devices for providing prolonged drug therapy |
31 Jan, 2018
(7 years ago)
| Expired |
| US6919373 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US6930129 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US8163798 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US8629179 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US9000038 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US9029416 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
| US9144549 | Methods and devices for providing prolonged drug therapy |
31 Jul, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Concerta's drug page
3. Ditropan Xl
Ditropan Xl is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5674895
(Pediatric)
| Dosage form comprising oxybutynin |
22 Nov, 2015
(9 years ago)
| Expired |
| US5840754
(Pediatric)
| Dosage form comprising oxybutynin |
22 Nov, 2015
(9 years ago)
| Expired |
| US5912268
(Pediatric)
| Dosage form and method for treating incontinence |
22 Nov, 2015
(9 years ago)
| Expired |
| US6262115
(Pediatric)
| Method for the management of incontinence |
22 Nov, 2015
(9 years ago)
| Expired |
| US5674895 | Dosage form comprising oxybutynin |
22 May, 2015
(10 years ago)
| Expired |
| US5840754 | Dosage form comprising oxybutynin |
22 May, 2015
(10 years ago)
| Expired |
| US5912268 | Dosage form and method for treating incontinence |
22 May, 2015
(10 years ago)
| Expired |
| US6262115 | Method for the management of incontinence |
22 May, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ditropan Xl's drug page
4. Invega Hafyera
Invega Hafyera is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11666697 | Methods for ensuring resuspension of paliperidone palmitate formulations |
24 Nov, 2041
(16 years from now)
| Active |
| US11304951 | Dosing regimens associated with extended release paliperidone injectable formulations |
07 May, 2041
(15 years from now)
| Active |
| US11324751 | Dosing regimens associated with extended release paliperidone injectable formulations |
07 May, 2041
(15 years from now)
| Active |
| US12208100 | Dosing regimens associated with extended release paliperidone injectable formulations |
07 May, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Hafyera's drug page
5. Invega Sustenna
Invega Sustenna is protected by 9 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9439906 | Dosing regimen associated with long acting injectable paliperidone esters |
26 Jan, 2031
(5 years from now)
| Active |
| US6555544
(Pediatric)
| Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
10 May, 2019
(6 years ago)
| Expired |
| US6555544 | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
10 Nov, 2018
(6 years ago)
| Expired |
| US6077843
(Pediatric)
| Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
12 Nov, 2017
(7 years ago)
| Expired |
| US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
12 May, 2017
(8 years ago)
| Expired |
| US5254556
(Pediatric)
| 3-piperidinyl-1,2-benzisoxazoles |
15 Apr, 2014
(11 years ago)
| Expired |
| US5254556 | 3-piperidinyl-1,2-benzisoxazoles |
15 Oct, 2013
(11 years ago)
| Expired |
| US5352459
(Pediatric)
| Use of purified surface modifiers to prevent particle aggregation during sterilization |
16 Jun, 2013
(12 years ago)
| Expired |
| US5352459 | Use of purified surface modifiers to prevent particle aggregation during sterilization |
16 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Sustenna's drug page
Explore Our Curated Drug Screens
6. Invega Trinza
Invega Trinza is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10143693 | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
05 Apr, 2036
(10 years from now)
| Active |
| US6077843
(Pediatric)
| Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
12 Nov, 2017
(7 years ago)
| Expired |
| US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
12 May, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Trinza's drug page
7. Invokamet
Invokamet is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11576894 | Combination therapy for the treatment of diabetes |
06 Jul, 2030
(5 years from now)
| Active |
| US7943582
(Pediatric)
| Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Aug, 2029
(4 years from now)
| Active |
| US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Feb, 2029
(3 years from now)
| Active |
| US8513202
(Pediatric)
| Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Jun, 2028
(2 years from now)
| Active |
| US7943788
(Pediatric)
| Glucopyranoside compound |
14 Jan, 2028
(2 years from now)
| Active |
| US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Dec, 2027
(2 years from now)
| Active |
| US7943788 | Glucopyranoside compound |
14 Jul, 2027
(2 years from now)
| Active |
| US8222219
(Pediatric)
| Glucopyranoside compound |
11 Oct, 2025
(3 months from now)
| Active |
| US8222219 | Glucopyranoside compound |
11 Apr, 2025
(2 months ago)
| Expired |
| US8785403 | Glucopyranoside compound |
30 Jul, 2024
(11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokamet's drug page
8. Invokamet Xr
Invokamet Xr is protected by 10 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7943582
(Pediatric)
| Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Aug, 2029
(4 years from now)
| Active |
| US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Feb, 2029
(3 years from now)
| Active |
| US8513202
(Pediatric)
| Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Jun, 2028
(2 years from now)
| Active |
| US7943788
(Pediatric)
| Glucopyranoside compound |
14 Jan, 2028
(2 years from now)
| Active |
| US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Dec, 2027
(2 years from now)
| Active |
| US7943788 | Glucopyranoside compound |
14 Jul, 2027
(2 years from now)
| Active |
| US8222219
(Pediatric)
| Glucopyranoside compound |
11 Oct, 2025
(3 months from now)
| Active |
| US8222219 | Glucopyranoside compound |
11 Apr, 2025
(2 months ago)
| Expired |
| US8785403 | Glucopyranoside compound |
30 Jul, 2024
(11 months ago)
| Expired |
| US6723340 | Optimal polymer mixtures for gastric retentive tablets |
25 Oct, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokamet Xr's drug page
9. Invokana
Invokana is protected by 10 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10617668
(Pediatric)
| Pharmaceutical formulations |
11 Nov, 2031
(6 years from now)
| Active |
| US10617668 | Pharmaceutical formulations |
11 May, 2031
(5 years from now)
| Active |
| US7943582
(Pediatric)
| Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Aug, 2029
(4 years from now)
| Active |
| US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
26 Feb, 2029
(3 years from now)
| Active |
| US8513202
(Pediatric)
| Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Jun, 2028
(2 years from now)
| Active |
| US7943788
(Pediatric)
| Glucopyranoside compound |
14 Jan, 2028
(2 years from now)
| Active |
| US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
03 Dec, 2027
(2 years from now)
| Active |
| US7943788 | Glucopyranoside compound |
14 Jul, 2027
(2 years from now)
| Active |
| US8222219
(Pediatric)
| Glucopyranoside compound |
11 Oct, 2025
(3 months from now)
| Active |
| US8222219 | Glucopyranoside compound |
11 Apr, 2025
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokana's drug page
10. Levaquin
Levaquin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6806256
(Pediatric)
| Taste masked liquid pharmaceutical compositions |
26 Aug, 2022
(2 years ago)
| Expired |
| US6806256 | Taste masked liquid pharmaceutical compositions |
26 Feb, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levaquin's drug page
11. Ortho Evra
Ortho Evra is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5876746 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
20 Nov, 2015
(9 years ago)
| Expired |
| US5972377 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
07 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortho Evra's drug page
12. Ortho Tri-cyclen Lo
Ortho Tri-cyclen Lo is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6214815
(Pediatric)
| Triphasic oral contraceptive |
09 Dec, 2019
(5 years ago)
| Expired |
| US6214815 | Triphasic oral contraceptive |
09 Jun, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortho Tri-cyclen Lo's drug page
13. Razadyne
Razadyne is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6099863 | Fast-dissolving galanthamine hydrobromide tablet |
06 Jun, 2017
(8 years ago)
| Expired |
| US6358527 | Fast-dissolving galanthamine hydrobromide tablet |
06 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Razadyne's drug page
14. Razadyne Er
Razadyne Er is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7160559 | Controlled release galantamine composition |
20 Dec, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Razadyne Er's drug page
15. Risperdal
Risperdal is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6224905
(Pediatric)
| Biconvex rapidly disintegrating dosage forms |
10 Dec, 2017
(7 years ago)
| Expired |
| US6224905 | Biconvex rapidly disintegrating dosage forms |
10 Jun, 2017
(8 years ago)
| Expired |
| US5648093
(Pediatric)
| Pharmaceutical and other dosage forms |
15 Jan, 2015
(10 years ago)
| Expired |
| US5453425
(Pediatric)
| Risperidone oral formulation |
11 Jan, 2015
(10 years ago)
| Expired |
| USRE39181
(Pediatric)
| Aqueous risperidone formulations |
11 Jan, 2015
(10 years ago)
| Expired |
| US5648093 | Pharmaceutical and other dosage forms |
15 Jul, 2014
(10 years ago)
| Expired |
| US5453425 | Risperidone oral formulation |
11 Jul, 2014
(10 years ago)
| Expired |
| USRE39181 | Aqueous risperidone formulations |
11 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Risperdal's drug page
16. Risperdal Consta
Risperdal Consta is protected by 24 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6667061
(Pediatric)
| Preparation of injectable suspensions having improved injectability |
25 Nov, 2020
(4 years ago)
| Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(5 years ago)
| Expired |
| US6194006
(Pediatric)
| Preparation of microparticles having a selected release profile |
30 Jun, 2019
(6 years ago)
| Expired |
| US6379703
(Pediatric)
| Preparation of microparticles having a selected release profile |
30 Jun, 2019
(6 years ago)
| Expired |
| US6596316
(Pediatric)
| Preparation of microparticles having a selected release profile |
30 Jun, 2019
(6 years ago)
| Expired |
| US6194006 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(6 years ago)
| Expired |
| US6379703 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(6 years ago)
| Expired |
| US6596316 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(6 years ago)
| Expired |
| US5792477
(Pediatric)
| Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
02 Nov, 2017
(7 years ago)
| Expired |
| US5916598
(Pediatric)
| Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 Nov, 2017
(7 years ago)
| Expired |
| US6403114
(Pediatric)
| Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 Nov, 2017
(7 years ago)
| Expired |
| US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
| US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
| US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
| US5688801
(Pediatric)
| Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
18 May, 2015
(10 years ago)
| Expired |
| US5688801 | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
18 Nov, 2014
(10 years ago)
| Expired |
| US5965168
(Pediatric)
| Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 May, 2014
(11 years ago)
| Expired |
| US6110921
(Pediatric)
| Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 May, 2014
(11 years ago)
| Expired |
| US6368632
(Pediatric)
| Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 May, 2014
(11 years ago)
| Expired |
| US7547452
(Pediatric)
| Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 May, 2014
(11 years ago)
| Expired |
| US5965168 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 Nov, 2013
(11 years ago)
| Expired |
| US6110921 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 Nov, 2013
(11 years ago)
| Expired |
| US6368632 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 Nov, 2013
(11 years ago)
| Expired |
| US7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
19 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Risperdal Consta's drug page
17. Sporanox
Sporanox is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6407079 | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
18 Jun, 2019
(6 years ago)
| Expired |
| US5707975 | Oral formulations on an antifungal |
13 Jan, 2015
(10 years ago)
| Expired |
| US5633015 | Beads having a core coated with an antifungal and a polymer |
27 May, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sporanox's drug page
18. Spravato
Spravato is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11883526 | Esketamine for the treatment of depression |
18 Feb, 2040
(14 years from now)
| Active |
| US10869844 | Methods for the treatment of depression |
10 Sep, 2035
(10 years from now)
| Active |
| US11173134 | Methods for the treatment of depression |
10 Sep, 2035
(10 years from now)
| Active |
| US11311500 | Methods for the treatment of depression |
10 Sep, 2035
(10 years from now)
| Active |
| US11446260 | Pharmaceutical composition of S-ketamine hydrochloride |
14 Mar, 2034
(8 years from now)
| Active |
| US8785500 | Intranasal administration of ketamine to treat depression |
05 Mar, 2033
(7 years from now)
| Active |
| US9592207 | Intranasal administration of ketamine to treat depression |
20 Mar, 2027
(1 year, 8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spravato's drug page
19. Topamax
Topamax is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7125560
(Pediatric)
| Pharmaceutical composition of topiramate |
01 Sep, 2019
(5 years ago)
| Expired |
| US7125560 | Pharmaceutical composition of topiramate |
01 Mar, 2019
(6 years ago)
| Expired |
| US5998380
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US6503884
(Pediatric)
| Migraine treatment method using topiramate and related compounds |
13 Apr, 2016
(9 years ago)
| Expired |
| US7018983
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US7498311
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US5998380 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
| US6503884 | Migraine treatment method using topiramate and related compounds |
13 Oct, 2015
(9 years ago)
| Expired |
| US7018983 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
| US7498311 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Topamax's drug page
20. Topamax Sprinkle
Topamax Sprinkle is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7125560
(Pediatric)
| Pharmaceutical composition of topiramate |
01 Sep, 2019
(5 years ago)
| Expired |
| US7125560 | Pharmaceutical composition of topiramate |
01 Mar, 2019
(6 years ago)
| Expired |
| US5998380
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US6503884
(Pediatric)
| Migraine treatment method using topiramate and related compounds |
13 Apr, 2016
(9 years ago)
| Expired |
| US7018983
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US7498311
(Pediatric)
| Treatment of migraine |
13 Apr, 2016
(9 years ago)
| Expired |
| US5998380 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
| US6503884 | Migraine treatment method using topiramate and related compounds |
13 Oct, 2015
(9 years ago)
| Expired |
| US7018983 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
| US7498311 | Treatment of migraine |
13 Oct, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Topamax Sprinkle's drug page
21. Ultram
Ultram is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6339105
(Pediatric)
| Analgesic regimen |
12 Apr, 2020
(5 years ago)
| Expired |
| US6339105 | Analgesic regimen |
12 Oct, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultram's drug page
22. Xarelto
Xarelto is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10828310
(Pediatric)
| Reducing the risk of cardiovascular events |
31 Jul, 2039
(14 years from now)
| Active |
| US10828310 | Reducing the risk of cardiovascular events |
31 Jan, 2039
(13 years from now)
| Active |
| US9539218
(Pediatric)
| Prevention and treatment of thromboembolic disorders |
17 Aug, 2034
(9 years from now)
| Active |
| US9539218 | Prevention and treatment of thromboembolic disorders |
17 Feb, 2034
(8 years from now)
| Active |
| US9415053
(Pediatric)
| Solid, orally administrable pharmaceutical composition |
13 May, 2025
(a month ago)
| Expired |
| US7157456
(Pediatric)
| Substituted oxazolidinones and their use in the field of blood coagulation |
28 Feb, 2025
(4 months ago)
| Expired |
| US9415053 | Solid, orally administrable pharmaceutical composition |
13 Nov, 2024
(7 months ago)
| Expired |
| US7157456 | Substituted oxazolidinones and their use in the field of blood coagulation |
28 Aug, 2024
(10 months ago)
| Expired |
| US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation |
11 Dec, 2020
(4 years ago)
| Expired |
| US7592339 | Substituted oxazolidinones and their use in the field of blood coagulation |
11 Dec, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xarelto's drug page